|Free Dividend Report|
|Stock Splits Calendar|
|LPTN Stock Split History|
|Preferred Stock Newsletter|
|LPTN Options Chain|
|Stock Message Boards|
LPTN (LPTN) has 1 split in our LPTN split history database. The split for LPTN took place on June 13, 2016. This was a 1 for 14 reverse split, meaning for each 14 shares of LPTN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 71.4285714285714 share position following the split.
When a company such as LPTN conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LPTN split history from start to finish, an original position size of 1000 shares would have turned into 71.4285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into LPTN shares, starting with a $10,000 purchase of LPTN, presented on a split-history-adjusted basis factoring in the complete LPTN split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-23.60%|
|Apollo Endosurgery is a biotechnology company focused on the discovery and development of lipidomic-based therapeutics antibodies, a field of medical science that targets bioactive signaling lipids to treat a range of human diseases. Co. has developed three product candidates: Lpathomab, which is a humanized monoclonal antibody (mAb) against lysophosphatidic acid for neuropathic pain, chemo-induced pain, traumatic brain injury, and fibrosis; iSONEP, which is the ocular formulation of sonepcizumab, a mAb against sphingosine-1-phosphate for age-related macular degeneration, RPE detachment, and other retinal diseases; and ASONEP, which is the systemic formulation of sonepcizumab for cancer. According to our LPTN split history records, LPTN has had 1 split.|
|LPTN Split History Table|
|06/13/2016||1 for 14|
|Healthcare Stock Splits|
|LPTN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|